Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4895]

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non...

ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis

ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer

SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after breast-conserving surgery

SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after...

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for immune cell therapy of solid cancer

New technology for inhibiting T cell exhaustion and reinvigorating exhausted T cells, which is essential for...

$FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation$

FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation

How AI found the words to kill cancer cells

How AI found the words to kill cancer cells

More from ecancer